Abstract:C1 inhibitor self-administration for the treatment of HAE allows patients to quickly treat attacks at home, potentially reducing attack severity. The results also demonstrate the benefit of self-administered routine prevention therapy in a real-world patient population. Self-administered therapy potentially allows patients to gain greater control over their attacks, resulting in a reduction in healthcare utilization.
“…Self‐administration is crucial for an effective on‐demand therapy as early treatment in the course of an attack has been shown to be more effective and may prevent complications. This effect is independent of the on‐demand medication used (see recommendation 3 and text) and facilitated by the skill of the self‐administrator or home therapy partner . Similarly, self‐administration facilitates long‐term prophylaxis.…”
Section: Patient Support Home Therapy and Self‐administration And Omentioning
confidence: 99%
“…Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity . As early treatment is facilitated by self‐administration, all patients with HAE‐1/2 should be considered for home therapy and self‐administration training . All C1‐INH concentrates and icatibant are licensed for self‐administration, although approved product indications vary around the world.We recommend that HAE attacks are treated with either C1‐INH, ecallantide, or icatibant (18/20).Evidence grade: A; Strength of recommendation: Strong, 90% agreement.…”
Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up‐to‐date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1‐inhibitor (type 1) and HAE with dysfunctional C1‐inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should HAE‐1/2 be defined and classified?, (2) How should HAE‐1/2 be diagnosed?, (3) Should HAE‐1/2 patients receive prophylactic and/or on‐demand treatment and what treatment options should be used?, (4) Should HAE‐1/2 management be different for special HAE‐1/2 patient groups such as pregnant/lactating women or children?, and (5) Should HAE‐1/2 management incorporate self‐administration of therapies and patient support measures?
“…Self‐administration is crucial for an effective on‐demand therapy as early treatment in the course of an attack has been shown to be more effective and may prevent complications. This effect is independent of the on‐demand medication used (see recommendation 3 and text) and facilitated by the skill of the self‐administrator or home therapy partner . Similarly, self‐administration facilitates long‐term prophylaxis.…”
Section: Patient Support Home Therapy and Self‐administration And Omentioning
confidence: 99%
“…Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity . As early treatment is facilitated by self‐administration, all patients with HAE‐1/2 should be considered for home therapy and self‐administration training . All C1‐INH concentrates and icatibant are licensed for self‐administration, although approved product indications vary around the world.We recommend that HAE attacks are treated with either C1‐INH, ecallantide, or icatibant (18/20).Evidence grade: A; Strength of recommendation: Strong, 90% agreement.…”
Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up‐to‐date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1‐inhibitor (type 1) and HAE with dysfunctional C1‐inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should HAE‐1/2 be defined and classified?, (2) How should HAE‐1/2 be diagnosed?, (3) Should HAE‐1/2 patients receive prophylactic and/or on‐demand treatment and what treatment options should be used?, (4) Should HAE‐1/2 management be different for special HAE‐1/2 patient groups such as pregnant/lactating women or children?, and (5) Should HAE‐1/2 management incorporate self‐administration of therapies and patient support measures?
“…Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity [89][90][91][92]. As early treatment is facilitated by self-administration, all patients with HAE-1/2 should be considered for home therapy and self-administration training [6,90,[93][94][95]. All C1-INH concentrates and icatibant are licensed for self-administration, although approved product indications vary around the world.…”
Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.
“…Regular home visits by healthcare professionals to administer lipo‐PGE1 might impose an extra burden on resources and might be impractical in various regions. Although patients can be taught to perform intravenous self‐administration, this imposes additional requirements on healthcare systems because several teaching sessions are needed for the successful completion of training 37 . Therefore, the use of lipo‐PGE1 may be restricted to patients given in‐center dialysis or patients undergoing home PD who are able to visit local healthcare facilities (e.g., clinics) to receive intravenous injection of drugs.…”
Social and healthcare improvements have prolonged individuals' lifespan worldwide, while they have resulted in an increased number of patients with end-stage renal disease (ESRD). 1 Peritoneal dialysis (PD) is extensively applied in the treatment of ESRD, with comparable outcomes to hemodialysis, including preservation of residual renal function, 2 being cost-effective, and higher quality of life. 3 In recent years, PD utilization has greatly attracted clinicians' attention in China, and over 250,000 patients have received PD according to the statistics reported in 2012. 4 However, peritoneal transport function gradually diminishes with the extended use of PD, and can eventually lead to ultrafiltration failure. [5][6][7] The dialysate/plasma creatinine ratio (D/Pcr) and the mass transfer area coefficient (MTAC) for urea (MTAC-urea) and creatinine (MTAC-creatinine) are commonly used indicators to assess peritoneal transport of small molecular solutes. 8 A specific correlation was reported between D/Pcr and MTAC-creatinine, and a change in MTAC can influence the effective peritoneal surface area. 9 In addition to the transport of creatinine and other small molecular
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
